• Mon news: Ventyx gets boost from Sanofi. PhRMA IRA legal challenge gets new life. AZ breast cancer drug disappoints. Teva’s once-monthly schizophrenia med. AZ gets FDA approval for first self-administered flu vaccine. See more on our front page

German biotech CatalYm cashes in on early-stage cancer data with $150M series D

cafead

Administrator
Staff member
  • cafead   Jul 16, 2024 at 12:02: PM
via On the heels of early-stage data for monoclonal antibody visugromab showing “impressive and lasting responses” among patients with difficult to treat cancers, CatalYm has secured a $150 million series D.

article source
 

<